- Home
- CMMB vs MDCX Comparison
CMMB vs MDCX Comparison
Compare CMMB & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CMMB | MDCX |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8M | 15.9M |
| IPO Year | 2023 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CMMB | MDCX |
|---|---|---|
| Price | $1.92 | $0.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $25.00 | $14.50 |
| AVG Volume (30 Days) | 61.8K | ★ 1.5M |
| Earning Date | 05-21-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.67 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $47.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $0.25 |
| 52 Week High | $3.86 | $3.05 |
Technical Indicators
Market Signals| Indicator | CMMB | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 62.20 | 38.81 |
| Support Level | $1.41 | N/A |
| Resistance Level | $2.21 | $0.41 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 81.10 | 7.96 |
Price Performance
Historical ComparisonAbout CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.